No Data
No Data
Leerink Partners Maintains AnaptysBio(ANAB.US) With Buy Rating
Positive Outlook on AnaptysBio: Buy Rating Based on Undervaluation and Promising Pipeline
AnaptysBio Price Target Raised to $51.00/Share From $40.00 by Wells Fargo
AnaptysBio Is Maintained at Overweight by Wells Fargo
AnaptysBio Analyst Ratings
$ANAB Stock Is up 16% Today. Here's What We See in Our Data.
damoose :![heart ❤️](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/2764-fe0f.png)
Yanfang Kuang : Thank you
74693490 : How much time do you spend on Stocks every day? I remember one time you posted on your Watchlist in the middle of the night, and then at five in the morning the next day you were commenting again. Overextending yourself like this will cause your body to collapse.
Day Lily : Thank you
)
(silent stalker #45,328
Veteran Analyst : Do you use a stock scanner to do the screening? Which software is good? Thanks.
View more comments...